While the effectiveness of galangin has been previously demonstrated in the treatment of RA [14,15], the present study aimed to investigate the potential mechanism of galangin in LPS-treated rheumatoid arthritis fibroblast-like synovial cells (RAFLSs) in vivo in terms of the mTOR/PI3K/AKT signaling pathway. The gene discussed is AKT1; the disease is rheumatoid arthritis.